

DCVMN COVID-19 COMMITTEE REPORT



DCVMN
Developing Countries Vaccine
Manufacturers Network

DCVMN Annual General Meeting (AGM)
20 – 22 October 2022
Pune, India

Objectives of the COVID-19 Committee

1. Prime COVID-19 vaccine candidates,
2. Disseminate technical information relating to COVID-19 vaccine development
3. Solutions provided by organizations such as CEPI, etc,
4. Assess and share technologies important for COVID vaccine development
5. Develop and support solid bases for statements to support DCVMN dialogue with global stakeholders and in public meetings

Protecting
people from
global diseases
since 2000.



**Organization of the committee
(June 19th 2020)**

Chair : Adriansjah Azhari (Bio Farma, Indonesia)

Co-chair : Raches Ella (Bharat Biotech, India)

Secretary : Apoorv Kumar (Bharat Biotech, India)

Members :

1. Indian Immunologicals, India
2. Panacea, India
3. SII, India
4. BioE, India
5. Pasteur Institute, India
6. Zhifei, China
7. Bravovax, China
8. BCHT, China
9. Inovax, China
10. CNBG, China
11. St Petersburg Scientific Research Institute of Vaccines and Sera, Russia
12. Biomanguinhos, Brazil
13. Singernium, Argentina
14. Bionet Asia, Thailand



**Organization of the committee
(As of Feb 10th 2022)**

Chair : Adriansjah Azhari (Bio Farma, Indonesia)

Co-chair : Parag Nagakar (Serum Institute of India)

Secretary : Sandra O Cho (Instituto Butantan, Brazil)

Members :

1. Indian Immunologicals, India
2. Panacea, India
3. SII, India
4. BioE, India
5. Pasteur Institute, India
6. Zydus Lifesciences Limited, India
7. Zhifei, China
8. Bravovax, China
9. BCHT, China
10. Inovax, China
11. CNBG, China
12. St Petersburg Scientific Research Institute of Vaccines and Sera, Russia
13. Biomanguinhos, Brazil
14. Singernium, Argentina
15. Bionet Asia, Thailand



DCVMN COVID-19 Committee

- First meeting held : June 19th 2020
- Meetings held triweekly : per June 10th 2021
monthly every second Thursday
- Sub- committees :
 - Clinical trials : Raches Ella (Lead) – Bharat Biotech
 - Partnerships : Yuri Vasiliev (Lead) – St Petersburg Scientific
Research Institute of Vaccines and Sera
 - Replacement : Apoorv Kumar – Bharat Biotech
 - Quality Control : Sunil Gairola (Lead) – Serum Institute of India

DCVMN COVID Committee

Meeting agenda :

Routine :

- Epidemiological updates
- Updates on total vaccine doses administered
- Partnership updates
- Updates on CEPI initiatives
- Reports from sub committees

Others :

- Joint meeting with Regulatory Systems Working Group (Feb 18th 2021)
- Presentations from DCVMN members
- Group discussion with invited speaker
- Webinars



DCVMN COVID Committee

Presentations by DCVMN members

Name	Institution	Date of Presentation	Presentation topic
Dr. Weining Meng	SINOVAC, China	June 10 th 2021	Clinical development of Sinovac COVID-19 vaccine
Dr. Sameer Naik	Serum Institute of India	Feb 10 th 2022	Understanding COVID-19 vaccines – challenges ahead
Dr. Gecilmara Salviato	Butantan, Brazil	March 10 th 2022	Booster dose vaccines
Dr. Andrew Wong	Walvax, China	April 14 th , 2022	COVID-19 vaccine candidates in mRNA platform
Dr. Parag Nagarkar	Serum Institute of India	June 8 th 2022	WHO EUL procedure – the challenges

Presentations by invited speakers

Name	Institution	Date of Presentation	Presentation
Dr Jakob Cramer	CEPI	Dec 3 rd , 2020	Webinar: An overview of COVID vaccine clinical trial results & some challenges
Dr Matthew Downham	CEPI	Dec 9 th , 2021	Scenarios on COVID variants – the challenges
Dr Matt Linley	Airfinity	Jan 25 th , 2022	Webinar : Dynamic demand forecasting for COVID-19 vaccines

Participation of DCVMN members in CEPI's initiatives

SWAT teams membership

	Leads	Core team members	Extended team members
Enabling sciences	Paul Kristiansen (CEPI) & (BMGF or WHO, TBC)	IFPMA (Gert Schepers/JNJ), BMGF (TBC), CEPI Task Force Leads (Carolyn Clark and Valentina Bernasconi), CEPI regulatory (Deb Yeskey/ Svein Rune Andersen), NIH/ACTIV (TBC), WHO (Ivana Knezevic), DCVMN (Weining Meng/Sinovac)	CEPI participants and additional experts
Clinical Development and Operations	Jakob Cramer (CEPI) & Peter Dull (BMGF)	NIH/NIAID (Hilary Marston), IFPMA (Thomas Breuer/GSK and Stephen Lockhart/Pfizer), DCVMN (Ricardo Palacios Gomez/Butantan Institute), Robert Chen (SPEAC/BC), Statistics, CEPI Epi (Gabrielle Breugelmanns), CEPI regulatory (Deb Yeskey/ Svein Rune Andersen), WHO (Ana Maria Henao Restrepo), LSHTM (Peter Smith), PATH (David Kaslow)	CEPI participants and additional experts
Manufacturing	Ingrid Kromann/Nicolas Havelange (CEPI) & David Robinson (BMGF)	IFPMA (Norio Tamura/Shionogi, Mike Thein/Merck, Mike King), DCVMN (Adriansjah Azhari/ Biofarma, Indonesia), WHO (Carmen Rodriguez Hernandez, Ivana Knezevic), Jim Robinson (CEPI CMC-SM), CEPI regulatory (Deb Yeskey/ Svein Rune Andersen), Gavi (Dominique Maugeais)	CEPI participants and additional experts
Regulatory support			
Regulatory Advisory Group (RAG)	Deb Yeskey/ Svein Rune Andersen (CEPI), WHO & regulators	Emer Cooke (WHO), Marion Gruber (FDA), Marco Cavaleri (EMA), David John Wood (WHO) & other regulators TBC	

Slides courtesy of CEPI

Information courtesy of CEPI

CMC platform protocol templates Working Groups

Objective : Build CMC platform protocol templates that are “pre-approved”/pre-agreed by worldwide regulators.

Aim : To streamline and accelerate vaccine development and to allow quicker access

- Ready-to-use tool based on agreed baseline and understanding

Two areas: 1) comparability and 2) manufacturing process validation

First draft : Feb 2023

Industry participants

1. DCVMN

Bio Farma
 Biological E
 Bio-Manguinhos / Fiocruz
 BioVac
 CanSino BIO
 Instituto Butantan
 Dohme (MSD)
 Institut Pasteur Dakar
 Sinergium Biotech
 Walvax

2. Non DCVMN

Astra Zeneca
 CureVac
 GlaxoSmithKline
 Innovative Biotech Nigeria
 Johnson & Johnson - Janssen
 Merck Sharp and
 Quantoom Bioscience
 Sanofi
 Seqirus
 Touchlight

Thank You



DCVMN

Developing Countries Vaccine
Manufacturers Network